By developing a multi-pronged approach to immunotherapy centered around Trilytes, KOSMAS Therapeutics attempts an improved elimination of cancer stem cells to attack cancer at its core.
Unlike other targeted agents, KOSMAS’ tri-specific Trilytes carry two binding heads for simultaneous recognition of two distinct antigens on the same cancer cells and cancer stem cells. Subsequently, Trilytes bind a Natural Killer (NK) cell via its strongest activating receptor, which then kills the malignant cell with high speed and efficacy.
Cancer stem cells allow many types of cancer to resist chemotherapy. They replenish the cancer cell mass and form life-threatening relapsed disease and metastases. KOSMAS’ Trilytes uniquely attack these resistant cells, which will result in deeper and longer lasting remissions, prolonged survival and an improved quality of a patient’s life.
Our team of dedicated scientists, physicians and thought-leaders have decades of experience in cancer biology, pathogenetics, immunology and the design of antibody-derived recombinant proteins. It is our primary goal to advance KT1 to the clinic for currently unmet needs of patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), and we have the team and technology to do so.
What started in the group of Georg Fey, PhD, former professor of Genetics at the University of Erlangen-Nuremberg, has evolved into a radically new approach for a preferential elimination of cancer stem cells over bulk cancer cells and corresponding normal cells.
